The present inventions relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol. Especially, the present invention relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol from 3,3,5-trimethylcyclohexanone and phenol in the presence of a gaseous acidic catalyst. The preparation comprises a first drying step and a second drying step wherein in the second drying step the temperature is increased in comparison to first drying step or in the second drying step the pressure is lowered in comparison to first drying step, or in second drying step both the temperature is increased and the pressure is lowered in comparison to the first drying step (d1).

The present inventions relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol. Especially, the present invention relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol from 3,3,5-trimethylcyclohexanone and phenol in the presence of a gaseous acidic catalyst. The preparation comprises a first drying step and a second drying step wherein in the second drying step the temperature is increased in comparison to first drying step or in the second drying step the pressure is lowered in comparison to first drying step, or in second drying step both the temperature is increased and the pressure is lowered in comparison to the first drying step (d1).

Provided is a novel compound having a selective activating effect on ERβ. The present invention provides a compound represented by the following formula (1) wherein R.sup.1 represents a cycloalkyl group having 3 to 8 carbon atoms, an alkenyl group having 2 to 6 carbon atoms and optionally substituted with a halogen atom, a 5-membered nitrogen-containing heteroaryl group, a 4- to 6-membered cyclic amino group, an alkanoylamino group having 2 to 6 carbon atoms and optionally substituted with a halogen atom, a 1-trifluoromethyl-1-hydroxymethyl group, or a 1-methylpropyl group; R.sup.2 to R.sup.5 are the same or different and each represent a hydrogen atom or a fluorine atom; and R.sup.6 represents a hydrogen atom or an alkanoyl group having 2 to 5 carbon atoms, or a salt thereof.

##STR00001##

The present invention relates to cocrystals of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol and a zwitterion coformer, processes for their preparation, and their use as a medicament and for the purification of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. The invention also relates to compositions comprising the cocrystal.

The present invention relates to cocrystals of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol and a zwitterion coformer, processes for their preparation, and their use as a medicament and for the purification of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. The invention also relates to compositions comprising the cocrystal.

The present invention relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol (BP-TMC). Especially, the present invention relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol (BP-TMC) from 3,3,5-trimethylcyclohexanone (TMC-one) and phenol in the presence of a gaseous acidic catalyst. The preparation is preferably conducted continuously. It is an object of the present invention to prevent that solids, especially crystallized BP-TMC, more especially crystallized BP-TMC-phenol-adduct, block the outlet of the dosing valve for the gaseous acidic acid when the gaseous acidic acid is dosed into the reaction mixture comprising TMC-one and phenol in a reaction vessel.

The present invention relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol (BP-TMC). Especially, the present invention relates to the preparation of 3,3,5-trimethylcyclohexylidene bisphenol (BP-TMC) from 3,3,5-trimethylcyclohexanone (TMC-one) and phenol in the presence of a gaseous acidic catalyst. The preparation is preferably conducted continuously. It is an object of the present invention to prevent that solids, especially crystallized BP-TMC, more especially crystallized BP-TMC-phenol-adduct, block the outlet of the dosing valve for the gaseous acidic acid when the gaseous acidic acid is dosed into the reaction mixture comprising TMC-one and phenol in a reaction vessel.

Disclosed are substituted (4′-hydroxylphenyl)cycloalkane compounds and substituted (4′-hydroxylphenyl)cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered for treating diseases associated with ER activity, such as neurological, psychiatric, and/or cell proliferative diseases and disorders as well as for enhancing memory consolidation in subjects in need thereof.

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

A polysubstituted benzene compound, preparation method thereof, and method of using the same. The compound has a formula I or I′, where X represents carbon, sulfur, or oxygen; R.sup.1 represents a C.sub.1-16 alkyl, C.sub.2-16 alkenyl, or C.sub.2-10 alkynyl; R.sup.2 represents hydrogen, halogen, C.sub.1-16 alkyl, C.sub.2-16 alkenyl, or C.sub.2-10 alkynyl; or an aryl group or a substituted aryl group by 1-5 groups selected from halogen, C.sub.1-26 alkyl, C.sub.1-3 halogenated alkyl, O—C.sub.1-3 alkyl, hydroxyl, amino, nitro, cyano group, aldehyde group and ester group; or a heteroaryl group or a substituted heteroaryl group by 1-5 groups selected from halogen, C.sub.1-26 alkyl, C.sub.1-3 halogenated alkyl, O—C.sub.1-3 alkyl, hydroxyl, amino, nitro, cyano group, aldehyde group and ester group; the heteroaryl group is a 3-10-membered heteroaryl group including N, S, O, or a combination thereof.